What is Vertex Pharmaceuticals's non-deductible aipr&d?

Vertex Pharmaceuticals (VRTX) reported non-deductible aipr&d of 373.8% in Q4 2024.

What does non-deductible aipr&d mean?

The tax impact of research and development costs from acquisitions that cannot be deducted from taxable income.

This increase may warrant attention — for this metric, lower values are generally preferred.

StatementIncome Statement

SectionOther

CategoryRisk

SignalLower is better

VolatilityModerate

First reportedQ4 2023

Last reportedQ4 2024Feb 13, 2026

An increase indicates higher non-deductible acquisition costs, which can inflate the effective tax rate and reduce net income.

This metric represents the impact of non-deductible acquired in-process research and development (AIPR&D) costs on the c...

Common in biotech and pharma companies that frequently acquire smaller firms to bolster their R&D pipelines.

Metric ID: other_effective_income_tax_rate_reconciliation_nondeduct_44267a

2 periods

	Q4 '23	Q4 '24
Value	0%	373.8%

Range0% – 373.8%

What is Vertex Pharmaceuticals's non-deductible aipr&d?: Vertex Pharmaceuticals (VRTX) reported non-deductible aipr&d of 373.8% in Q4 2024.
What does non-deductible aipr&d mean?: The tax impact of research and development costs from acquisitions that cannot be deducted from taxable income.